Eli Lilly releases "promising" data for tirzepatide in fatty liver indication
Novo Nordisk rival Eli Lilly has been testing its active ingredient, tirzepatide, in new indications after its success on the diabetes and obesity markets.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novo Nordisk's semaglutide shows potential against addiction
For subscribers
Eli Lilly to invest USD 5.3bn in obesity drug production
For subscribers